Revolution Medicines has filed to raise $100 million in an IPO. The anticipated fundraising haul will bankroll development of a pipeline of RAS programs up to the…

Cancer has been on the public radar for many years now and, although several drugs exist to treat the disease, none of them are effective…

Whether a day trader or a long-term investor, we often examine research released by industry experts, brokers and analysts with a view to uncovering the…

We maintain our Buy rating and are increasing our price target to A$0.16from A$0.09. The drivers to our valuation chance include: (1) adjustment to base…

Prescient Therapeutics (PTX) shares rose 60 per cent this morning after expanding its Phase 1b study in patients with acute myeloid leukaemia This study comes…

Cancer drug developer Prescient Therapeutics (ASX: PTX) is expanding its Phase 1b study in patients with acute myeloid leukemia (AML) after three patients were completely eradicated of…

This week we were joined in office by Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke for an investor and industry update in…

Humankind has been trying to find a cure for cancer for thousands of years. Today, we may have reached a point where we know enough…

Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company which is engaged in small molecule drug development focused on new cancer drugs. The company is known…